日本动脉粥样硬化协会（JAS）2022年动脉粥样硬化性心血管疾病预防指南。 - Suppr

Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2022.

作者信息

Okamura Tomonori, Tsukamoto Kazuhisa, Arai Hidenori, Fujioka Yoshio, Ishigaki Yasushi, Koba Shinji, Ohmura Hirotoshi, Shoji Tetsuo, Yokote Koutaro, Yoshida Hiroshi, Yoshida Masayuki, Deguchi Juno, Dobashi Kazushige, Fujiyoshi Akira, Hamaguchi Hirotoshi, Hara Masumi, Harada-Shiba Mariko, Hirata Takumi, Iida Mami, Ikeda Yoshiyuki, Ishibashi Shun, Kanda Hideyuki, Kihara Shinji, Kitagawa Kazuo, Kodama Satoru, Koseki Masahiro, Maezawa Yoshiro, Masuda Daisaku, Miida Takashi, Miyamoto Yoshihiro, Nishimura Rimei, Node Koichi, Noguchi Midori, Ohishi Mitsuru, Saito Isao, Sawada Shojiro, Sone Hirohito, Takemoto Minoru, Wakatsuki Akihiko, Yanai Hidekatsu

机构信息

Preventive Medicine and Public Health, Keio University School of Medicine.

Department of Internal Medicine, Teikyo University School of Medicine.

出版信息

J Atheroscler Thromb. 2024 Jun 1;31(6):641-853. doi: 10.5551/jat.GL2022. Epub 2023 Dec 19.

DOI:10.5551/jat.GL2022

PMID:38123343

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11150976/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/46bf/11150976/b68df8f9a855/31_GL2022_1.jpg

相似文献

Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2022.

J Atheroscler Thromb. 2024 Jun 1;31(6):641-853. doi: 10.5551/jat.GL2022. Epub 2023 Dec 19.

Comprehensive risk management for the prevention of cardiovascular disease: executive summary of the Japan Atherosclerosis Society (JAS) guidelines for the diagnosis and prevention of atherosclerotic cardiovascular diseases in Japan -- 2012.

J Atheroscler Thromb. 2013;20(7):603-15. doi: 10.5551/jat.15867. Epub 2013 Jul 25.

Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2017.

J Atheroscler Thromb. 2018 Sep 1;25(9):846-984. doi: 10.5551/jat.GL2017. Epub 2018 Aug 22.

Women. Executive Summary of the Japan Atherosclerosis Society (JAS) Guidelines for the Diagnosis and Prevention of Atherosclerotic Cardiovascular Diseases in Japan―2012 Version.

J Atheroscler Thromb. 2014;21(4):291-5. doi: 10.5551/jat.19711. Epub 2013 Dec 10.

Treatment B) drug therapy: executive summary of the Japan Atherosclerosis Society(JAS) guidelines for the diagnosis and prevention of atherosclerotic cardiovascular diseases in Japan--2012 version.

J Atheroscler Thromb. 2013;20(12):850-60. doi: 10.5551/jat.19166. Epub 2013 Dec 10.

Treatment A) lifestyle modification: executive summary of the Japan Atherosclerosis Society(JAS) guidelines for the diagnosis and prevention of atherosclerotic cardiovascular diseases in Japan--2012 version.

J Atheroscler Thromb. 2013;20(12):835-49. doi: 10.5551/jat.18820. Epub 2013 Oct 29.

Executive summary of the Japan Atherosclerosis Society (JAS) guidelines for the diagnosis and prevention of atherosclerotic cardiovascular diseases in Japan -2012 version.

J Atheroscler Thromb. 2013;20(6):517-23. doi: 10.5551/jat.15792. Epub 2013 May 11.

Diabetes mellitus. Executive summary of the Japan Atherosclerosis Society (JAS) guidelines for the diagnosis and prevention of atherosclerotic cardiovascular diseases in Japan--2012 version.

J Atheroscler Thromb. 2014;21(2):93-8. doi: 10.5551/jat.19349. Epub 2013 Dec 10.

Coronary artery disease. Executive summary of the Japan Atherosclerosis Society (JAS) guidelines for the diagnosis and prevention of atherosclerotic cardiovascular diseases in Japan--2012 version.

J Atheroscler Thromb. 2014;21(2):86-92. doi: 10.5551/jat.19158. Epub 2013 Dec 10.

Other types of primary hyperlipoproteinemia(hyperlipidemia). Executive summary of the Japan Atherosclerosis Society (JAS) guidelines for the diagnosis and prevention of atherosclerotic cardiovascular diseases in Japan--2012 version.

J Atheroscler Thromb. 2014;21(2):82-5. doi: 10.5551/jat.19141. Epub 2013 Dec 10.

引用本文的文献

Machine learning-based high-benefit approach versus traditional high-risk approach in statin therapy: the Shizuoka Kokuho database study.

Sci Rep. 2025 Jul 29;15(1):27627. doi: 10.1038/s41598-025-11236-y.

The incidence of vascular adverse events and usefulness of novel risk assessment tool in Japanese patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors.

Cardiooncology. 2025 Jul 19;11(1):68. doi: 10.1186/s40959-025-00366-x.

Role of Arterial Stiffness and Carotid Intima-Media Thickness on Subclinical Atherosclerosis and Cardiovascular Risk Assessment.

Cardiol Ther. 2025 Jul 19. doi: 10.1007/s40119-025-00428-2.

The Role of Polygenic Risk Score in the General Population: Current Status and Future Prospects.

J Atheroscler Thromb. 2025 Sep 1;32(9):1079-1097. doi: 10.5551/jat.RV22039. Epub 2025 Jul 4.

Association of hepatic steatosis with increased plasma xanthine oxidoreductase activity: MedCity21 health examination registry.

Metabol Open. 2025 Jun 13;27:100374. doi: 10.1016/j.metop.2025.100374. eCollection 2025 Sep.

Relationship Between Metabolic Syndrome Indicators Within Reference Ranges and Sarcopenia in Older Women-A 4-Year Longitudinal Study.

Geriatrics (Basel). 2025 Jun 3;10(3):76. doi: 10.3390/geriatrics10030076.

Impact of Angiotensin-Converting Enzyme Inhibitor on Coronary Artery Calcification Evaluated by Intravascular Ultrasound: A Retrospective Cohort Study.

Health Sci Rep. 2025 Jun 11;8(6):e70900. doi: 10.1002/hsr2.70900. eCollection 2025 Jun.

Impact of personality prototypes on app engagement and weight loss in a mobile app-based lifestyle modification support program for individuals with obesity and non-communicable diseases.

Digit Health. 2025 Jun 9;11:20552076251347891. doi: 10.1177/20552076251347891. eCollection 2025 Jan-Dec.

ANGPTL3: A Breakthrough Target in Treatment for Dyslipidemia and Atherosclerosis.

J Atheroscler Thromb. 2025 Sep 1;32(9):1071-1078. doi: 10.5551/jat.RV22038. Epub 2025 Jun 5.

Association of Social Participation with Cardiovascular Risk Factors: A Systematic Review.

J Atheroscler Thromb. 2025 Aug 1;32(8):897-910. doi: 10.5551/jat.RV22035. Epub 2025 May 24.

本文引用的文献

Development and Validation of a Risk Prediction Model for Atherosclerotic Cardiovascular Disease in Japanese Adults: The Hisayama Study.

J Atheroscler Thromb. 2023 Dec 1;30(12):1966-1967. doi: 10.5551/jat.ER61960. Epub 2023 Oct 24.

Effect of a Community-Based Program to Accelerate Referral to Physicians for Individuals at High-Risk of Lifestyle-Related Diseases: A Cluster Randomized Trial.

J Atheroscler Thromb. 2023 Oct 1;30(10):1389-1406. doi: 10.5551/jat.64100. Epub 2023 Mar 5.

Guidelines for the Diagnosis and Treatment of Pediatric Familial Hypercholesterolemia 2022.

J Atheroscler Thromb. 2023 May 1;30(5):531-557. doi: 10.5551/jat.CR006. Epub 2023 Jan 20.

Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk.

N Engl J Med. 2022 Nov 24;387(21):1923-1934. doi: 10.1056/NEJMoa2210645. Epub 2022 Nov 5.

Cardiovascular Family History Increases the Risk of Disease Recurrence After a First Myocardial Infarction.

J Am Heart Assoc. 2021 Dec 7;10(23):e022264. doi: 10.1161/JAHA.121.022264. Epub 2021 Nov 30.

Risk Classification for Metabolic Syndrome and the Incidence of Cardiovascular Disease in Japan With Low Prevalence of Obesity: A Pooled Analysis of 10 Prospective Cohort Studies.

J Am Heart Assoc. 2021 Dec 7;10(23):e020760. doi: 10.1161/JAHA.121.020760. Epub 2021 Nov 19.

Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies-a consensus statement from the European Atherosclerosis Society.

Eur Heart J. 2021 Dec 14;42(47):4791-4806. doi: 10.1093/eurheartj/ehab551.

Smoking cessation, but not reduction, reduces cardiovascular disease incidence.

Eur Heart J. 2021 Oct 21;42(40):4141-4153. doi: 10.1093/eurheartj/ehab578.

International Exercise Recommendations in Older Adults (ICFSR): Expert Consensus Guidelines.

J Nutr Health Aging. 2021;25(7):824-853. doi: 10.1007/s12603-021-1665-8.

Predictive Value of the Cardio-Ankle Vascular Index for Cardiovascular Events in Patients at Cardiovascular Risk.

J Am Heart Assoc. 2021 Aug 17;10(16):e020103. doi: 10.1161/JAHA.120.020103. Epub 2021 Aug 7.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2022.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献

本文引用的文献